PNP to crack down on illegal sale of ivermectin | Inquirer News

PNP to crack down on illegal sale of ivermectin

/ 04:37 AM April 12, 2021

MANILA, Philippines — The Philippine National Police is targeting the unauthorized sale and distribution for human use of the veterinary drug ivermectin.

Maj. Gen. Albert Ignatius, chief of the PNP Criminal Investigation and Detection Group (CIDG), said on Sunday that the CIDG would work closely with the Food and Drug Administration (FDA) in the crackdown on individuals engaged in the distribution of “fake, unregistered or unlicensed” ivermectin, an antiparasitic drug.

“We strongly advise the public to seek professional help and opinion before using the said drug and buy only from authorized sources,” he said.

The FDA recently granted a compassionate special permit for ivermectin use on patients with COVID-19 to only one hospital, which has not been identified.

—Jeannette I. Andrade
Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

For more news about the novel coronavirus click here.
What you need to know about Coronavirus.
For more information on COVID-19, call the DOH Hotline: (02) 86517800 local 1149/1150.

The Inquirer Foundation supports our healthcare frontliners and is still accepting cash donations to be deposited at Banco de Oro (BDO) current account #007960018860 or donate through PayMaya using this link.

TAGS: coronavirus Philippines, COVID-19, Ivermectin

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our newsletter!

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

© Copyright 1997-2024 INQUIRER.net | All Rights Reserved

This is an information message

We use cookies to enhance your experience. By continuing, you agree to our use of cookies. Learn more here.